Shots: The collaboration follows the existing partnership b/w J&J and BARDA while the company expects to initiate the clinical studies of selected vaccine candidates by Sept’2020 with the anticipated first […]readmore
Tags : Johnson & Johnson
Shots: The collaboration leads to the starting of pre-clinical testing of multiple vaccine prospects, intending to identify the vaccine candidate for clinical studies, by the month-end Janssen will utilize its AdVac […]readmore
Shots: The study will assess the Heartline study app on iPhone, the ECG app and irregular rhythm notification feature on Apple Watch in improving the health outcomes including reduction in […]readmore
WHO to Accelerate Global Research and Innovation Against Corona Virus Published: Feb 06, 2020 | Tags: WHO, Accelerate, Global, Research, Innovation, Against, Corona Virus 2. Curis Amends its Existing Collaboration […]readmore
ProQR’s QR-421a Receives FDA’s Rare Pediatric Disease Designation for Retinitis Pigmentosa Published: Jan 30, 2020 | Tags: ProQR, QR-421a, Receives, FDA, Rare Pediatric Disease Designation, Retinitis Pigmentosa 2. Eli Lilly’s Fast-Acting […]readmore
Shots: J&J launches a multi-pronged response to the Coronavirus (2019-nCoV or Wuhan coronavirus) outbreak and collaborating with others to screen a library of antiviral therapies The vaccine program leverages Janssen’s […]readmore
1. RedHill Terminates its 2014 Deal with Salix Pharmaceuticals for RHB-106 Published: Jan 03, 2019 | Tags: 2014, Deal, RedHill, RHB-106, Salix Pharmaceuticals, Terminates 2. Innate’s Lumoxiti (moxetumomab pasudotox-tdfk) Receives […]readmore
Shots: Pulamtrix to receive $7.2M up front, milestones up to $2M on completion of P-Ib study of RV1162/PUR1800 for patients with COPD, with on-track for year-end 2020 from J&J’s Lung […]readmore
1. Luye Pharma Reports Submission of NDA to the US FDA for LY03005 Published: Dec 26, 2019 | Tags: FDA, Luye Pharma, LY03005, NDA, reports, Submission, US 2. Immunomedics Reports […]readmore
Shots: J&J acquires TARIS Biomedical while TARIS to continue research in Lexington, Massachusetts and will also become part of Janssen R&D’s Oncology Therapeutic Area. Additionally, the companies will focus on […]readmore